AMGN
Amgen
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world’s largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. Amgen’s Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.In 2018, the company’s largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA. Amgen sponsors the Tour of California.
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 147.45B; Volume: 456.12K; AvgVol 3m: 2.58M; Beta: 0.81;
Cost estimate:
P/E: 20.29; EPS: 12.24; EPS growth quarter/prev quarter: -14.70%;
EPS growth this year: 2.00%; EPS growth past 5 years: 14.00%;
EPS ttm: 12.24;
P/S: 6.34; P/B: 13.94; P/Cashflow: 13.49; P/FCF: 23.36;
Sales: 24.30B; Sales growth quarter/prev quarter: 5.70%; Sales growth past 5 years: 3.10%;
Profitability:
Gross Margin: 78.20%; Profit Margin: 30.00%; Operating Margin: 37.90%;
ROA – return on assets: 11.90%; ROE – return on equity: 71.70%; LT Debt/Equity: 3.20; Total Debt/Equity: 3.21;
Dividend: 6.40; Dividend Yield (%): 2.52%;
Insider Ownership: 0.20%; Insider Transactions:-0.46%;
Institutional Ownership: 78.20%; Institutional Transactions: -0.69%;
Data update: 07/10/2020.